Pharmaceuticals Subscribe

Global Bio-Surfactants Market 2015-2019

Published in ; US $ 3000 Onwards; Publisher: Infiniti Research Limited

Bio-surfactants are an assorted gathering of active molecules that can be produced by integrating living cells or micro-organisms, such as bacteria, fungi, and yeast. Bio-based surfactants can be produced from oleochemical raw materials such as vegetable oils, animal fats, sucrose, […]

Latest Chinese Guidance for Development, Evaluation, License Approval of Biosimilars

Published in ; US $ 750 Onwards; Publisher: Access China Management Consulting Ltd

Summary China has an indispensable biosimilar market for overseas and multinational pharmaceutical companies. Historical data shows 40 per cent of China’s $1.5bn recombinant biologic product sales come from biosimilars, which have enjoyed approximately 25-30 per cent CAGR over the past […]

Global Soy Isoflavone Industry Report 2015

Published in ; US $ 2800 Onwards; Publisher: QYResearch Group

This is a professional and in-depth study on the current state of the Soy Isoflavone industry. The report provides a basic overview of the industry including definitions, classifications, applications and industry chain structure. The Soy Isoflavone market analysis is provided […]

Austria Pharmaceuticals and Healthcare Report Q3 2015

Published in ; US $ 1295 Onwards; Publisher: Business Monitor International

BMI View: The Austrian pharmaceutical and healthcare sectors are well developed and stable, offering some of the most attractive opportunities in the region. Nevertheless, our pharmaceutical and healthcare expenditure growth expectations remain resiliently subdued over the next few years, which […]

Colombia Pharmaceuticals and Healthcare Report Q3 2015

Published in ; US $ 1295 Onwards; Publisher: Business Monitor International

BMI View: The government’s push for improvement to the Colombian healthcare sector, combined with the country’s growing burden of chronic conditions and reliance on imported drugs will keep the healthcare and pharmaceutical markets on positive trajectories. However, the country’s expanding […]

Hong Kong Pharmaceuticals and Healthcare Report Q3 2015

Published in ; US $ 1295 Onwards; Publisher: Business Monitor International

BMI View: Financial constrains coupled with the lack of healthcare facilities and medical professional in the public sector meant that the private healthcare sector will play an increasingly important role in Hong Kong. This shift also means that patients will […]

Hungary Pharmaceuticals and Healthcare Report Q3 2015

Published in ; US $ 1295 Onwards; Publisher: Business Monitor International

BMI View: Hungary’s attractiveness to multinational drugmakers will be impeded by onerous regulatory burden, pricing pressures and punitive taxes on pharmaceutical companies. Combined, these factors will impede growth in pharmaceutical sales over the short-term. Consumer demand for over-the-counter medicines and […]

Japan Pharmaceuticals and Healthcare Report Q3 2015

Published in ; US $ 1295 Onwards; Publisher: Business Monitor International

BMI View: The Japanese pharmaceutical market will become increasingly challenging for multinational drugmakers. This comes as the use of generic drugs has begun to gain momentum, creating a more competitive environment for innovative medicines. In addition, top line growth for […]

Pakistan Pharmaceuticals and Healthcare Report Q3 2015

Published in ; US $ 1295 Onwards; Publisher: Business Monitor International

BMI View: Medicine sales in Pakistan will continue to grow significantly from a low base. Underpinning this trajectory includes a reform in the country’s pricing environment that will see scope for an increase in pharmaceutical prices. This will in turn […]

Poland Pharmaceuticals and Healthcare Report Q3 2015

Published in ; US $ 1295 Onwards; Publisher: Business Monitor International

BMI View: The National Health Fund and the Agency for Health Technology Assessment will continue to impede the reimbursement of innovative drugs in Poland over the short term, given their current focus on budgetary restraint. Over the longer term, we […]